Odaily Morning News
1. The top holder on the TRUMP token banquet leaderboard holds about 2.2 million TRUMP, valued at approximately $9 million;
2. The founder of ShapeShift bought 21,293 ETH within 6 days, spending a total of $44.52 million;
3. The probability of Polymarket's "Trump will visit China before March 31" briefly dropped to 49%, with a 24-hour decline of 16%;
4. Trump: We are in talks with Iran, but I believe they are not ready yet;
5. A suspect accused of stealing crypto assets controlled by the US government has been arrested;
6. Ethereum Foundation sold 5,000 ETH to BitMine for $10.2 million;
7. WSJ: The US government may announce a multinational joint escort for the Strait of Hormuz as early as this week;
8. Robinhood released February operating data: crypto trading volume increased 9% month-on-month and 74% year-on-year;
9. IEA: Record reserve crude oil will be immediately released to the Asian market, while Europe and the US will have to wait until the end of March;
10. Venus Protocol is suspected to have suffered a flash loan attack, with large-scale liquidation of THE.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Morgan Stanley senior bond investor turns bullish on US Treasuries for the first time in ten years
US Stock Movement | SuperX AI Technology (SUPX.US) once fell more than 2.5%, hitting an intraday low of $6.46
SuperX AI Technology's stock price declined, falling more than 2.5% at one point.
BUZZ-Pacira BioSciences participated in a Viatris acquisition deal worth 1.65 billions dollars
Latest Update October 8 – Pacira BioSciences (PCRX.O) shares surged by 44%, hitting a more than three-year high at $36.30. If the rally holds, PCRX is poised for its largest single-day gain on record. Pharmaceutical company Viatris (VTRS.O) will acquire Pacira BioSciences in a $1.65 billion cash deal, offering $36.50 per share. The offer represents a premium of approximately 44.8% over Pacira’s recent closing price of $25.20. The transaction will add Pacira’s non-opioid pain medications Exparel and Zilretta to Viatris' product portfolio. Viatris shares fell 2.6% to $17.04. JPMorgan stated: “We believe this acquisition will not significantly alter VTRS' overall financial profile in the short or long term, and expect Exparel’s sales to gradually decline post-2030 due to generic market entry.” Both parties expect to complete the transaction by the end of 2026. Including intraday fluctuations, PCRX shares have risen 40.2% year-to-date, while VTRS has gained 36.8%. (For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. As automated translation may contain errors or lack the necessary context, Reuters does not guarantee the accuracy of automated translated texts and provides them for readers’ convenience only. Reuters assumes no liability for any damage or losses resulting from the use of automated translation.)
Crypto prices
More
